Connect your AI

Integra LifeSciences IART Long-Term Debt

Long-Term Debt at other companies

Becton, Dickinson and CompanyBDX

$14.71B-16.8%

StrykerSYK

$14.22B-1.1%

AxogenAXGN

$0-100%

MedtronicMDT

$26.17B+2.1%

STERISSTE

$1.81B-11.3%

ITG

Integer HoldingsITGR

$1.25B+1.3%

Other financials

Income statement

Revenue$391.9M+2.4%

Gross profit$217.0M+11.6%

Operating income$11.5M+174%

Net income-$4.6M+81.7%

EPS (diluted)-$0.06+81.8%

Balance sheet

Cash & equivalents$236.8M-1.0%

Total debt$2.0B+3.2%

Total equity$1.0B-31.6%

Total assets$3.6B-11.7%

Cash flow

Operating cash flow$9.8M+187%

CapEx$14.8M-48.7%

Free cash flow-$5.0M+87.4%

Valuation

Market cap$1.38B+53.4%

Enterprise value$3.12B+21.1%

P/S0.8×+0.3×

Profitability

Gross margin51.9%-1.6pp

Operating margin-29.8%-30.3pp

Net margin-30.1%—

FCF margin3.8%-6.3pp

Returns & leverage

Return on equity-38.6%—

Debt / equity1.9×+0.6×

Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:SecuredLongTermDebt.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Integra LifeSciences's long-term debt?: Integra LifeSciences (IART) reported long-term debt of $1.75B in Q1 2026.
How has Integra LifeSciences's long-term debt changed year-over-year?: Integra LifeSciences's long-term debt increased by 55.1% year-over-year, from $1.13B to $1.75B.
What is the long-term trend for Integra LifeSciences's long-term debt?: Over 5 years (2020 to 2025), Integra LifeSciences's long-term debt has grown at a 13.1% compound annual growth rate (CAGR), from $933.39M to $1.73B.
What does long-term debt mean?: Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.